Lee Fleisher, former CMO of CMS, calls for alignment between FDA approval and CMS coverage standards to ensure that patients who could benefit the most from iBCIs will have access in the future. (Shutterstock)
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
